|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
EP0464147B1
(en)
*
|
1989-03-21 |
2002-06-26 |
THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE |
Matrix metalloproteinase inhibitor peptides
|
|
US5698671A
(en)
|
1989-03-21 |
1997-12-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Metalloproteinase peptides
|
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
JP3017591B2
(ja)
*
|
1992-01-17 |
2000-03-13 |
富士薬品工業株式会社 |
抗ヒトｔｉｍｐ−２モノクローナル抗体の製法およびその利用
|
|
US6562596B1
(en)
|
1993-10-06 |
2003-05-13 |
Amgen Inc. |
Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6391265B1
(en)
|
1996-08-26 |
2002-05-21 |
Biosite Diagnostics, Inc. |
Devices incorporating filters for filtering fluid samples
|
|
EP2305027B1
(en)
|
1996-12-03 |
2014-07-02 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
|
US6045899A
(en)
|
1996-12-12 |
2000-04-04 |
Usf Filtration & Separations Group, Inc. |
Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters
|
|
DE69837544T2
(de)
|
1997-07-16 |
2007-12-20 |
Charm Sciences, Inc., Lawrence |
Testgerät und methode zur entdeckung von analyten in proben
|
|
JP2002507725A
(ja)
|
1998-03-16 |
2002-03-12 |
クイデル コーポレイション |
イムノアッセイデバイスおよび方法
|
|
US7214542B2
(en)
|
2003-01-30 |
2007-05-08 |
Michael Hutchinson |
Method of processing assay test results
|
|
WO2004096832A2
(en)
|
2003-04-29 |
2004-11-11 |
Children's Medical Center Corporation |
Novel antiangiogenic peptides
|
|
CN1833169A
(zh)
|
2003-08-11 |
2006-09-13 |
协和梅迪克斯株式会社 |
测量对象物测量器具、测量装置和测量方法
|
|
CA2574417C
(en)
|
2004-07-28 |
2010-09-28 |
F. Hoffmann-La Roche Ag |
Timp-2 as target/marker of beta cell failure
|
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
|
WO2007048100A2
(en)
|
2005-10-18 |
2007-04-26 |
The Government Of The United States, As Represented By The Secretary Of Health & Human Services |
Angio-inhibitory peptides derived from human timp-2
|
|
CN104391115B
(zh)
|
2008-10-21 |
2017-04-19 |
阿斯图特医药公司 |
用于诊断和预后肾损伤和肾衰竭的方法和组合物
|
|
US8900881B2
(en)
|
2008-12-30 |
2014-12-02 |
Jin Po Lee |
Quantitative analyte assay device and method
|
|
AU2010306581B2
(en)
|
2009-10-16 |
2015-03-19 |
Omeros Corporation |
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
|
|
KR20120123056A
(ko)
|
2009-12-20 |
2012-11-07 |
아스튜트 메디컬 인코포레이티드 |
신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
|
|
EP2531620B1
(en)
|
2010-02-05 |
2016-12-14 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
US9903865B2
(en)
|
2010-03-31 |
2018-02-27 |
Sekisui Medical Co., Ltd. |
Assay, immunochromatographic test strip, and assay reagent kit for measuring an analyte, using a hematocrit correction
|
|
EP2585827A4
(en)
|
2010-06-23 |
2013-12-04 |
Astute Medical Inc |
METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
|
|
EP2621502A4
(en)
*
|
2010-09-30 |
2014-08-13 |
Nitto Denko Corp |
MODULATION OF TIMP1 AND TIMP2 EXPRESSION
|
|
TR201903235T4
(tr)
|
2011-08-26 |
2019-03-21 |
Astute Medical Inc |
Böbrek hasari ve böbrek yetmezli̇ği̇ni̇n tanilanmasi ve prognozuna yöneli̇k metotlar ve bi̇leşi̇mler.
|
|
WO2013086359A1
(en)
|
2011-12-08 |
2013-06-13 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
CN104603150A
(zh)
*
|
2012-04-20 |
2015-05-06 |
中央研究院 |
与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
|
|
EP2888282B1
(en)
|
2012-08-21 |
2018-03-14 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
ES2681955T3
(es)
|
2013-01-17 |
2018-09-17 |
Astute Medical, Inc. |
Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
|
|
US20160146832A1
(en)
|
2013-06-05 |
2016-05-26 |
Lakhmir S. Chawla |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
CA2920521A1
(en)
|
2013-08-07 |
2015-02-12 |
Astute Medical, Inc. |
Assays for timp2 having improved performance in biological samples
|
|
EA201690731A1
(ru)
|
2013-11-06 |
2016-10-31 |
Астьют Медикал, Инк. |
Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
|
|
CN105917229B
(zh)
|
2013-12-03 |
2019-04-26 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断和预后的方法和组合物
|
|
KR101605421B1
(ko)
*
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
|
WO2016164854A1
(en)
|
2015-04-09 |
2016-10-13 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
AU2017277305A1
(en)
|
2016-06-06 |
2018-12-20 |
Astute Medical, Inc. |
Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
|
|
ES2908239T3
(es)
|
2016-10-28 |
2022-04-28 |
Astute Medical Inc |
Uso de anticuerpos contra timp-2 para la mejora de la función renal
|
|
US11346846B2
(en)
|
2017-02-06 |
2022-05-31 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
WO2018187453A1
(en)
|
2017-04-05 |
2018-10-11 |
Astute Medical, Inc. |
Assays for timp2 having improved performance in biological samples
|
|
US20210025875A1
(en)
|
2017-05-07 |
2021-01-28 |
Astute Medical, Inc. |
Use of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 in the management of renal replacement therapy
|